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Objectives: Rituximab SC reduces administration times (~5 minutes) com-
pared with the IV route (~4 hours). We examined the extent of patient prefer-
ence for rituximab SC versus IV in the PrefMab and MabCute studies using the 
Rituximab Administration Satisfaction Questionnaire (RASQ). MethOds: In 
PrefMab (NCT01724021) patients with untreated CD20+ DLBCL/FL received 1 cycle 
of IV rituximab (375mg/m2) followed by either SC rituximab (1400mg, x3) then IV 
rituximab (x4), or IV rituximab (x3) then SC rituximab (x4), with chemotherapy. 
In MabCute (NCT01461928) patients with relapsed/refractory CD20+ indolent NHL 
received induction rituximab IV (375mg/m2; 1 cycle) then rituximab SC (1400mg; 
cycles 2–8) plus 6–8 chemotherapy cycles. RASQ evaluated preference by assessing 
patients’ perceptions of the impact of administration route and treatment satisfac-
tion. Conceptual validation of RASQ has been conducted and psychometric data 
will be reported. Results: Median RASQ scores for PrefMab were: convenience IV 
(n= 211) 58.3 (interquartile range: 41.7–75.0) and SC (n= 207) 83.3 (75.0–91.7); satisfac-
tion: IV (n= 211) 75.0 (62.5–87.5), SC (n= 208) 87.5 (75.0–100.0); impact on daily life: 
IV (n= 145) 50.0 (41.7–83.3), SC (n= 163) 83.3 (83.3–100.0); physical impact IV (n= 211) 
83.3 (66.7–100.0), SC (n= 208) 83.3 (75.0–100.0); psychological impact IV (n= 211) 80.0 
(65.0–90.0), SC (n= 208) 88.8 (75.0–95.0). SC administration was preferred by 80.3% 
and 85.9% of patients with IV or SC as most recent dose, respectively. Results were 
similar irrespective of treatment sequence. Median RASQ scores for MabCute 
(n= 92) were: convenience: IV 58.3 (33.3–66.7), SC 83.3 (66.7–83.3); satisfaction: IV 
62.5 (50.0–87.5), SC 87.5 (75.0–100.0); impact on daily life: IV 58.3 (41.7–66.7), SC 83.3 
(66.7–83.3); physical impact IV 75.0 (66.7–91.7), SC 83.3 (66.7–91.7); psychological 
impact IV 70.0 (60.0–85.0), SC 85.0 (75.0–95.0). cOnclusiOns: Consistent patient 
satisfaction and preference for SC versus IV rituximab was demonstrated in the 
PrefMab and MabCute studies. RASQ is a reliable and valid measure of patient treat-
ment preference.
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Objectives: We conducted a systematic literature review to identify published 
evidence from observational studies on the humanistic burden of multiple myeloma 
(MM). MethOds: We searched MEDLINE, Embase, EconLit, and the Cochrane Library 
for English-language articles and analysed these qualitatively. Results: The review 
identified 20 publications based on 18 observational studies; these were mainly 
cross-sectional in design (n= 14). Most studies (n= 15) examined populations with 
MM in general, typically without stating the proportion with relapsed (R) or relapsed 
and refractory (RR) MM. Fewer studies examined patients with newly-diagnosed 
MM (n= 2) or RMM/RRMM (n= 1). Health-related quality of life (HRQoL) was typically 
assessed using validated cancer-specific instruments (e. g., the EORTC-QLQ-C30: 
n= 9; and the MM-specific EORTC-QLQ-MY20: n= 4). On average, patients with MM 
had poorer HRQoL compared to the general population (n= 6), and compared to 
patients with certain other hematologic cancers (n= 2). MM patients whose disease 
duration ranged from diagnosis to 11 years had greater physical function impair-
ment (p< 0.001) than other hematologic cancer patients. Other complaints included 
fatigue, bone pain, tingling, and non-specific pain. Patients on active treatment had 
worse side effects than those in a first treatment-free interval (p< 0.001); the latter 
had better scores on HRQoL dimensions including role and social function, future 
perspectives, and body image (all p< 0.05). Between baseline and one year, patients 
experienced worsening on the EORTC-QLQ-C30 global health scale (p< 0.001) and 
in fatigue, nausea/vomiting, and pain scores (all p< 0.05). Symptomatic patients 
had lower physical functioning scores (p< 0.05) than asymptomatic patients; those 
with severe symptoms had lower EORTC-QLQ-C30 global health scores (p< 0.05; 
mild/moderate symptoms: p= NS). Fatigue, bone pain, and anaemia were associated 
with lower. cOnclusiOns: HRQoL in patients with MM deteriorates with disease 
duration, symptom severity, disease progression, or development of complications. 
This evidence suggests substantial unmet needs in MM patients.
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Objectives: There are approximately 2,000 hemophilia patients in Korea, but 
patient-reported outcome (PRO) studies involving a large number of hemophilia 
patients have been rarely studied. The aim of this study was to assess PROs in 
moderate to severe hemophilia patients in Korea. MethOds: It was a cross- 
sectional, multi-centered and observational study. Moderate to severe, male 
hemophilia patients aged 8 to 65 were recruited at 2 of Korea Hemophilia 
Foundations and 3 other pediatrics from November 2012 to September 2013. 
All patients completed self-reported questionnaires to measure patients’ char-
acteristics and PROs including health-related quality of life (HRQoL) and pro-
ductivity loss. HRQoL was examined using EQ-5D, ranged 0-1, which higher 
values indicate better HRQoL and Heamo-QoL, ranged 0-100, where higher val-
ues imply lower HRQoL. Productivity loss was estimated with absenteeism and 
presentism in terms of lost productivity time (LPT). Results: For a total of 605 
patients (mean age, 29.3 years; 88.6% with severe hemophilia) enrolled in this 
study, the mean scores of heamo-QoL and EQ-5D were 32.28 and 0.68 respec-
tively. The mean scores of EQ-5D in this study are comparable to 0.68 in rheu-
matoid arthritis patients from Korea Observational Study Network for Arthritis. 
Significantly lower EQ-5D was found in patients with the following clinical factors 
compared to those with reverse conditions; joint bleedings (0.68 vs. 0.73, p= .001), 
in platelet count. During recovery phase WBC count increased first followed by plate-
lets count production after 3-4 days. Among 1000 confirmed dengue fever patients 
812 were considered dengue hemorrhagic fever cases on the basis of clinical finding. 
In most of these cases (n= 783; 96.47%), directly proportional relation was observed 
between WBC and platelets count. cOnclusiOns: It is wrongly perceived in com-
munity that dengue virus infection is still progressing when platelets count is below 
normal even the white blood cells counts is getting better during recovery phase. 
White blood cells production during recovery phase is a good indicator about recov-
ery of disease rather than focused on platelets counts production.
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Objectives: To define the importance values assigned to the attributes of bio-
logical agents (BA) by Spanish rheumatologists and patients with rheumatic dis-
eases: rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis 
(PA). MethOds: Observational, cross-sectional design based on conjoint analy-
sis. RA, AS and PA patients diagnosed at least 2 years prior and currently or pre-
viously (≤ 1 year ago) receiving BA for a minimum of 1 year were consecutively 
recruited. Rheumatologists with at least 3 year experience on BAs participated. A 
literature review and 4 focus groups were undertaken to identify attributes and 
levels. Scenarios were selected using orthogonal design. Participants ranked 8 
scenarios from 1 (most preferred) to 8 (least preferred). Relative importance (RI) 
of attributes was calculated. Multivariate regression analysis was performed for 
each attribute. Results: 488 patients [male= 50.9%; mean (SD) age= 50.6 (12.06) 
years; RA= 33.8%, AS= 32.4%, PA= 33.8%; mean time from diagnosis= 12.6 (8.2) years] 
and 136 rheumatologists [male= 50.4%; mean age= 46.4 (9.1) years; mean time of 
practice= 16.7 (8.8) years] took part. Most important attributes selected by patients 
and physicians, respectively, were: ‘Pain relief and improvement of the functional 
capacity’ (RI= 49.1% and 48.9%); ‘Risk of adverse events’ (RI= 31.8% and 31.5%), 
‘Administration method’ (RI= 10.2% and 11.4%) and ‘Time to perceive the need for 
a new dose’ (RI= 9.0% and 8.2%). The ideal BA, for patients and physicians, should 
allow pain relief and an improvement of the functional capacity, with a low risk 
of adverse events, a long time prior to perceiving the need for a new dose and 
self-administration at home, when possible. cOnclusiOns: Although efficacy and 
safety are key for patients with rheumatic diseases and rheumatologists to make a 
choice over a BA, the need for a low frequency of administration and the administra-
tion method also play an important role as preference attributes for BAs in Spain.
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Objectives: Biological agents (BA) to treat rheumatic diseases are commonly 
administered by either the subcutaneous or the intravenous route. The objective 
of this study was to assess rheumatoid arthritis (RA), ankylosing spondylitis (AS) 
and psoriatic arthritis (PA) Spanish patients’ preferences over BA considering the 
administration route. MethOds: Observational, cross-sectional design. Participants 
were RA, AS and PA patients (diagnosed ≥ 2 years prior to study entry; currently 
or previously (≤ 1 year ago) receiving BA for a minimum of 1 year. Conjoint analy-
sis was performed to define preferences over 8 scenarios combining 4 attributes 
[‘Administration method’ (ADMINISTRATION), ‘Pain relief and improvement of the 
functional capacity’ (RELIEF), ‘Risk of adverse events’ (AE) and ‘Time until perceiv-
ing the need for a new dose’ related to the frequency of administration (TIME)]. 
Relative importance (RI) was calculated for patients on subcutaneous or intravenous 
administration, respectively. Results: A total of 488 patients [male= 50.9%; mean 
(SD) age= 50.6 (12.06) years; RA= 33.8%, AS= 32.4%, PA= 33.8%; mean time from diag-
nosis= 12.6 (8.2) years; receiving currently BA= 98.2%] were included. The patients 
currently receiving subcutaneous (n= 305) or intravenous (n= 174) administration 
with BA gave highest importance to ‘RELIEF’ (45.4% and 46.7%) and ‘AE’ (28.2% and 
31.8%), followed by ‘ADMINISTRATION’ (19.7% and 10.2%) and ‘TIME’ (6.7% and 11.3%, 
respectively). Both groups of patients preferred to stay on the same route of adminis-
tration, either subcutaneous or intravenous, they had been on. Moreover all patients 
considered most crucial a longer time until perceiving the need for a new dose (8 
over 4 over 2 over 1 week). cOnclusiOns: Spanish patients with rheumatic dis-
eases placed high importance on pain relief and risk of AEs as preference attributes 
for BAs. The frequency of administration (time until perceiving the need for a new 
dose) also plays a crucial role as all patients indicated their preference for lower vs. 
higher frequencies of BA administration.
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survey was developed for patients (adults/children) and caregivers. Patients were 
recruited by patient organisations in cystic fibrosis (CF), Prader–Willi syndrome 
(PWS), haemophilia (HEMO), Duchenne muscular dystrophy (DMD), epidermolysis 
bullosa (EB), fragile X syndrome (FXS), scleroderma (SCL), mucopolysaccharidosis 
(MPS), juvenile idiopathic arthritis (JIA) and histiocytosis (HIS). Demography amd 
main characteristics were recorded. Patients’ and caregivers’ health state was 
assessed by the EQ-5D-5L, disability and caregivers’ burden by the Barthel Index 
and Zarit Burden Interview questionnaires. Results: In Hungary, 296 Hungarian 
patients (children: 161, 54%) participated in the study (CF 110, PWS 5, HEMO 58, 
DMD 57, EB 6, FXS 12, SCL 38 and MPS 10 patients), no data were obtained in JIA and 
HIS. Mean age among adults/children was 37.0 (SD 16.1) / 9.6 (SD= 4.5) years, and 
disease duration was 18.5 (SD= 14.4) / 7.1 (SD= 4.5) years, respectively. The lowest 
average EQ-5D-5L score was found in MPS (0.134 / 0.070) and DMD (0.310 / 0.198) 
just alike with the Barthel Index (MPS: 35.6; DMD 58.0). Caregivers’ (N= 95) mean 
age was 39.2 (SD= 8.0) years and their EQ-5D-5L score (0.797, SD= 0.251) was not sig-
nificantly different from the general populations’ average. Satisfaction with health 
care (1-10 Likert scale) was the lowest in MPS, DMD and EB (mean 4.1, 5.2 and 
4.3). cOnclusiOns: Rare diseases induce substantial deterioration of patients’ 
quality of life and impose burden on caregivers. Taking an integrated approach our 
results can serve for international comparisons and facilitate further investigations 
in other orphan diseases.
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Objectives: The aim of the UK multi-centre LupusQoL Sensitivity Study is to 
assess whether the LupusQoL, a systemic lupus erythematosus (SLE) specific, 
health-related quality of life measure is sensitive to change when disease activ-
ity improves or deteriorates. MethOds: Patients with SLE experiencing a flare 
(baseline) & requiring an increase in treatment were recruited. Assessments were 
undertaken at baseline & monthly for 9 months & included BILAG-2004 disease 
activity index & the LupusQoL with 8 domains and scores ranging from 0 (worst) 
to 100 (best HRQoL). LupusQoL domain scores when disease activity improved or 
deteriorated between consecutive time-points are reported as mean changes, with 
95% CI constructed using robust standard errors to account for repeated patient 
assessments. Results: Mean (SD) age was 40.9 (12.8) & duration since diagno-
sis was 9.3 (8.1) years for the 101 patients recruited; 94% females, 62.6% white 
Caucasians. At baseline all mean LupusQoL domain scores were < 52. Scores for 
LupusQoL physical health (+4.0, 95%CI 1.9 to 6.1), pain (+7.7, 95%CI 4.8 to 10.5) & 
fatigue (+4.1, 95%CI 1.7 to 6.5) increased when BILAG improved. Scores for physi-
cal health (-4.9, 95% -9.4 to -0.4) and pain (-6.9, 95%CI -12.9 to -0.8) decreased with 
a major BILAG deterioration but changes with a minor deterioration were small 
and non-significant. The effects of improvements & deterioration in BILAG on 
the other LupusQoL domain scores were smaller. cOnclusiOns: Improvement 
and deterioration of LupusQoL domain scores for physical health, pain & fatigue 
domain scores was seen in patients with significant changes in disease activity 
over 1 month. Sensitivity to change of other LupusQoL domains in relation to 
changes in disease activity may need to be evaluated over a longer interval as the 
more emotive type of response to the disease & its consequences may be latent 
and therefore not evident at monthly intervals.
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Objectives: To assess the Quality of Life (QoL), focusing on level of pain, of patients 
submitted to surgical interventions with robotic technique in comparison with 
traditional approach in the Italian setting. MethOds: The prospective multicen-
tre study analysed the QoL of 699 patients submitted to surgical interventions, 
enrolled in 8 Italian Hospitals for the period February 2011-May 2014. The specialties 
were general, thoracic, gynecological surgery performed with open, manual lapa-
roscopic or robotic technique. Patients completed two questionnaires: one related 
to pain intensity during the hospitalization and one fulfilled at home related to 
pain intensity and its impact on daily activities, mood, relationship, sleep. Pain was 
measured using the scale of facial expressions corresponding to the Visual Analog 
Scale. For each intervention and specialty, linear regression for repeated measure, 
corrected by length of stay and use of analgesics, were performed to explain level 
of pain during hospitalization and at home, respectively. Results: Level of pain 
during hospitalization is significantly (p= 0.05) lower in general and gynecological 
robotic surgery versus the open technique, but not versus laparoscopic, while robotic 
thoracic surgery presents significant differences with laparoscopic but not with 
open surgery (p= 0.059). Level of pain at home is significantly different for robotic 
interventions versus open both in general and gynecological surgery; moreover, 
with respect to laparoscopic interventions, the differences are significant both in 
gynecological and in thoracic but not in general surgery. cOnclusiOns: The study 
gives us insightful knowledge about QoL, focusing on pain, of patients submitted to 
surgical interventions with robotic technique vs traditional surgery. Further analysis 
are in progress to combine results on QoL, not only referred to level of pain, with 
clinical severity and other indicators of clinical efficacy as length of stay, operating 
hemophilic joint health (0.67vs. 0.73, p< .001) or disability (0.65 vs. 0.70, p< .001) as 
similar as in the results of Haemo-QoL. With patients who were either on a job or 
students (n= 467, 77.2%), LPT was estimated at 127.81 hours per month on average. 
Of 467, patients with inhibitor or disability showed higher LPT compared to those 
without inhibitor (130.61 vs. 126.61 hours per month, p= 0.486) or disability. (132.27 
vs. 124.95 hours per month p=.087). cOnclusiOns: The study findings suggest that 
patients’ clinical characteristics should take into account for the management of 
hemophilia given patient-reported outcomes differed by clinical manifestations.
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Objectives: To assess the burden of LN in comparison to SLE patients without 
Nephritis (Non-LN) in routine clinical practices in EU. MethOds: A multi-center 
medical chart-review of adult (16-89yrs) SLE patients was conducted among rheu-
matologists and internal medicine physicians in UK/France/Germany/Italy/Spain 
(5EU). Physicians were recruited from a geographically representative sample in 
each country. Approx. 5 consecutive eligible persistent active or relapse remitting 
SLE patients currently managed as part of usual care were identified. Physicians 
abstracted de-identified patient data on disease characteristics, lab values and 
treatment patterns. LN and Non-LN cohorts were compared using descriptive 
statistics. Results: 168 LN patients and 569 non-LN patients with SLE were ana-
lyzed. Patient characteristics included (LN/Non-LN): age (yrs): 40.2/42.7; % Female: 
82.7/79.4; % Caucasian: 82.7%/88.8%; % full-time employment: 32.1/36.0; % part-time 
employment: 19.0%/22.0%. Among LN/Non-LN cohorts, frequency of clinic visits was: 
9.5wks/10.6wks, % currently receiving care in in-patient setting was: 14.9/8.8, % hos-
pitalized > = 1 in the past-year was: 49.4/29.7; mean # of organ manifestations was: 
3.9/3.0. Top-5 organ manifestations were (% LN/Non-LN): musculoskeletal: 85.1/90.8, 
mucocutaneous: 85.1/84.8, haematologic: 51.8/52.2, renal: 100.0/5.9, pulmonary: 
16.7/16.2; % experiencing a flare was (LN/Non-LN): 23.2/16.6. Renal biopsy was per-
formed in 87.5% (LN) and 4.0% (Non-LN) of patients. Steroids were used by 82.1% 
(LN) and 69.4% (Non-LN). % patients with low C3 and C4 was LN: 66.3/48.1/Non-LN: 
60.2/50.0; mean ESR scores were 40.2 (LN) and 36.8 (Non-LN). Among patients with 
available data, SELENA-SLEDAI scores were 11.5 (LN) and 8.5 (Non-LN). Humanistic 
burden (reported via physician ratings, on a scale of 0 (most impact) to 7 (least impact)) 
was (LN/Non-LN, mean scores): ability to perform every-day tasks: 5.0/5.3, ability to 
interact fully with family and friends: 5.4/5.6, and ability to work/keep employment: 
4.5/5.0. cOnclusiOns: LN cohorts had higher clinical and humanistic burden in 5EU 
in comparison to their non-LN SLE counterparts. Factors influencing the observed 
burden, including the therapeutic strategies used in these geographies warrant fur-
ther investigation to manage SLE, and LN in particular, optimally.
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Objectives: To qualitatively assess the impact of Psoriasis on patient 
QoL. MethOds: An ethnographic study with moderate/severe Psoriasis patients 
was conducted in 4EU (UK/France/Spain/Italy) and the US to explore patients’ views 
on treatment options and Psoriasis impact on QoL. Anthropologists and ethnog-
raphers spent several-hours with consented patients and filmed their behaviours 
inside and outside their homes in everyday situations. 175 hours of recordings/notes 
were analysed to identify QoL-related themes: self-image, psychological effects of 
psoriasis (e. g., anxiety/depression), life-style changes due to Psoriasis, relationship 
with family, friends and colleagues. Results: Study included 35 adult patients (4EU: 
20, US: 15; mean age: 39 yrs; female: 65%). Patients described their appearance with 
a sense of disgust and self-loathing. Feelings of frustration were often expressed due 
to a perceived lack of control of their lives. Prior to biologic initiation, daily rituals 
absorbed good part of their day, including waking up earlier to apply creams, going 
to work earlier to check their appearance and cover patches of dead skin. Due to 
lack of cultural discourse and patient’s difficulty in articulating Psoriasis’ impact, 
partners and family did not know how to react nor did they realize the full extent 
of the problem. Difficulty in getting appropriate psychological support needed left 
them with a feeling of resignation. As a result, majority dealt with their issues in 
isolation. Most patients experienced social discriminations due to Psoriasis which 
led some to lie about their disease, keeping it a secret. Biologic experienced patients 
noticed a significant improvement physically, but psychological scarring remained. 
Despite their regained confidence owing to the effectiveness of biologics, they still 
did not discuss their condition with family and friends. cOnclusiOns: Patients 
with Psoriasis experienced significantly lower quality of life and high psychological 
scarring. Ethnographic study design vividly depicted the unarticulated and emo-
tional impact of Psoriasis on patients’ everyday lives.
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Objectives: The Social Economic Burden and Health-Related Quality of Life in 
Patients with Rare Diseases in Europe (BURQOL-RD, http://www.burqol-rd.com/) 
project aimed to investigate disease burden and self-percieved health outcomes of 
patients and their caregivers in rare diseases in eight EU countries (Bulgaria, France, 
Germany, Hungary, Italy, Sweden, Spain, UK). MethOds: An online questionnaire 
